Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health

BACKGROUND: To review and summarize all U.S. Food and Drug Administration (FDA) approvals of programmed death (PD)‐1 and PD‐ligand 1 blocking antibodies (collectively referred to as PD‐[L]1 inhibitors) over a 6‐year period and corresponding companion/complementary diagnostic assays. MATERIALS AND ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Elaine, Pelosof, Lorraine, Lemery, Steven, Gong, Yutao, Goldberg, Kirsten B., Farrell, Ann T., Keegan, Patricia, Veeraraghavan, Janaki, Wei, Guo, Blumenthal, Gideon M., Amiri‐Kordestani, Laleh, Singh, Harpreet, Fashoyin‐Aje, Lola, Gormley, Nicole, Kluetz, Paul G., Pazdur, Richard, Beaver, Julia A., Theoret, Marc R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Immuno‐Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488782/
https://www.ncbi.nlm.nih.gov/pubmed/34196068
http://dx.doi.org/10.1002/onco.13887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488782/
https://www.ncbi.nlm.nih.gov/pubmed/34196068
http://dx.doi.org/10.1002/onco.13887

Ejemplares similares